DD3 Antibodies

Santa Cruz Biotechnology provides a broad selection of DD3 Antibodies for research focused on understanding DD3 protein functions. DD3 Antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). DD3, also known as PCA3, is a non-coding RNA that shows elevated expression in prostate cancer cells, serving as a significant biomarker for prostate cancer diagnosis and prognosis. Expression levels of DD3 can provide valuable insights into tumor progression and response to therapy, highlighting its significance in cancer research. DD3 research plays a vital role in developing targeted therapies and improving patient outcomes in prostate cancer treatment. Understanding DD3 expression patterns helps researchers identify potential therapeutic targets and develop more effective treatment strategies. Investigating DD3's molecular mechanisms contributes to a deeper understanding of prostate cancer biology. DD3 research supported by Santa Cruz Biotechnology monoclonal antibodies continues to advance scientific knowledge in cancer biology and therapeutic development.